Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Haemonetics (NYSE:HAE) in the last three months. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Insights from analysts’ 12-month price targets are revealed, presenting an average target of $107.5, a high estimate of $125.00, and a low estimate of $85.00. Experiencing a 1.08% decline, the current average is now lower than the previous average price target of $108.67. Analy…